Drug strategies for bladder cancer in the elderly: is there promise for the future?. (24th July 2019)

• Record Type: Journal Article
• Authors: Soria, Francesco; Mosca, Alessandra; Gontero, Paolo
• Is Part Of: Expert opinion on pharmacotherapy. Volume 20:Number 11(2019)
• Page Start: 1387
• Page End: 1396
• Publication Date: 2019-07-24
• Subjects: Elderly -- bladder cancer -- novel drugs -- systemic therapy; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2019.1615055
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction : Bladder cancer (BCa) is a disease that predominantly affects adult and elderly populations. As people live longer, it will become even more frequent and consequently represents a big health problem for health-care providers and is a challenging clinical dilemma. In the elderly, the treatment of BCa presents some peculiarities due to its more aggressive behavior and reduced patient reserves, impacting their response to medical and surgical therapies. Areas covered : The authors provide a non-systematic review of the literature using PubMed to obtain an overview of the therapeutic options for BCa in the elderly, from the low-risk non-muscle-invasive setting to muscle-invasive and advanced/metastatic disease. Expert opinion : The main challenge in the treatment of BCa in the elderly is represented by the need to find a compromise between the risk of under- and overtreatment. The wide spectrum of disease prognoses between low-risk non-muscle invasive BCa and invasive metastatic disease represents a perfect setting for a personalized approach. To pursue this aim, older patients need a multidisciplinary approach and clinical management, in order to optimize oncological outcomes as well as to face and support their frailty during cancer therapies.